NASDAQ:VCYT

Veracyte Stock Forecast, Price & News

$51.20
+4.39 (+9.38 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$46.81
$51.79
50-Day Range
$35.62
$52.97
52-Week Range
$28.82
$86.03
Volume1.26 million shs
Average Volume842,924 shs
Market Capitalization$3.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.77
30 days | 90 days | 365 days | Advanced Chart
Receive VCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.


Veracyte logo

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

999th out of 1,349 stocks

Medical Laboratories Industry

22nd out of 30 stocks

Analyst Opinion: 1.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Veracyte (NASDAQ:VCYT) Frequently Asked Questions

Is Veracyte a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Veracyte stock.
View analyst ratings for Veracyte
or view top-rated stocks.

What stocks does MarketBeat like better than Veracyte?

Wall Street analysts have given Veracyte a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Veracyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Veracyte's next earnings date?

Veracyte is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Veracyte
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) issued its quarterly earnings results on Thursday, July, 29th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.12. The biotechnology company had revenue of $55.11 million for the quarter, compared to analysts' expectations of $47.73 million. Veracyte had a negative trailing twelve-month return on equity of 4.05% and a negative net margin of 40.06%.
View Veracyte's earnings history
.

How has Veracyte's stock been impacted by COVID-19?

Veracyte's stock was trading at $23.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VCYT shares have increased by 117.4% and is now trading at $51.20.
View which stocks have been most impacted by COVID-19
.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200 million-$208 million, compared to the consensus revenue estimate of $197.90 million.

What price target have analysts set for VCYT?

10 Wall Street analysts have issued 12 month price targets for Veracyte's stock. Their forecasts range from $42.00 to $60.00. On average, they anticipate Veracyte's stock price to reach $53.44 in the next year. This suggests a possible upside of 4.4% from the stock's current price.
View analysts' price targets for Veracyte
or view top-rated stocks among Wall Street analysts.

Who are Veracyte's key executives?

Veracyte's management team includes the following people:
  • Marc A. Stapley, Chief Executive Officer & Director
  • Rebecca Chambers, Chief Financial Officer
  • Giulia C. Kennedy, Chief Scientific & Medical Officer
  • Richard T. Kloos, Executive Medical Director
  • William W. Zondler, Chief Information Officer & Senior Vice President

Who are some of Veracyte's key competitors?

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (9.95%), BlackRock Inc. (8.99%), Vanguard Group Inc. (8.85%), Artisan Partners Limited Partnership (7.06%), Invesco Ltd. (5.99%) and William Blair Investment Management LLC (5.70%). Company insiders that own Veracyte stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Mark Ho and Robert S Epstein.
View institutional ownership trends for Veracyte
.

Which major investors are selling Veracyte stock?

VCYT stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, William Blair Investment Management LLC, Bank of New York Mellon Corp, Jennison Associates LLC, Prudential Financial Inc., Goldman Sachs Group Inc., Vanguard Group Inc., and Dimensional Fund Advisors LP. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Giulia C Kennedy, John Walter Hanna Jr, Karin Eastham, Kevin K Gordon, and Mark Ho.
View insider buying and selling activity for Veracyte
or view top insider-selling stocks.

Which major investors are buying Veracyte stock?

VCYT stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Champlain Investment Partners LLC, Macquarie Group Ltd., State Street Corp, Bamco Inc. NY, Artisan Partners Limited Partnership, Bank of Montreal Can, and Eagle Asset Management Inc..
View insider buying and selling activity for Veracyte
or or view top insider-buying stocks.

How do I buy shares of Veracyte?

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $51.20.

How much money does Veracyte make?

Veracyte has a market capitalization of $3.63 billion and generates $117.48 million in revenue each year. The biotechnology company earns $-34,910,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis.

How many employees does Veracyte have?

Veracyte employs 320 workers across the globe.

What is Veracyte's official website?

The official website for Veracyte is www.veracyte.com.

Where are Veracyte's headquarters?

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 243-6300 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.